Literature DB >> 3281708

Effect of preoperative fusidic acid on the normal eyelid and conjunctival bacterial flora.

P B Taylor1, K F Tabbara, E M Burd.   

Abstract

A randomised trial comparing the topical application of 1% fusidic acid with 0.3% gentamicin solution in the reduction of the normal preoperative lid and conjunctival microbial flora was performed. Forty patients awaiting cataract surgery were randomly divided into two groups consisting of 20 patients each. The first group received a 1% microcrystalline suspension of fusidic acid, the second 0.3% gentamicin to the preoperative eye every two hours between 0600 and 2400 daily for 48 hours preoperatively. Cultures were obtained from both the lid margins and the conjunctival sac of both groups prior to antibiotic therapy and again in the operating theatre before surgery. Microbiological identification and colony counts were performed by standard laboratory methods. Staphylococcus epidermidis was the commonest micro-organism isolated. Statistical analysis revealed no significant differences in the ability of a 1% microcrystalline suspension of fusidic acid and 0.3% gentamicin in eliminating or reducing the normal preoperative conjunctival or lid flora.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281708      PMCID: PMC1041408          DOI: 10.1136/bjo.72.3.206

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

1.  Treatment of staphylococcal infections with "fucidin".

Authors:  R B CROSBIE
Journal:  Br Med J       Date:  1963-03-23

2.  Antibacterial activity in vitro of fucidin.

Authors:  M BARBER; P M WATERWORTH
Journal:  Lancet       Date:  1962-05-05       Impact factor: 79.321

3.  Antibiotic prophylaxis in cataract surgery.

Authors:  R P Burns; M Oden
Journal:  Trans Am Ophthalmol Soc       Date:  1972

4.  Bacterial endophthalmitis after cataract extraction. II. Incidence in 36,000 consecutive operations with special reference to preoperative topical antibiotics.

Authors:  H F Allen; A B Mangiaracine
Journal:  Arch Ophthalmol       Date:  1974-01

5.  Preoperatively administered antibiotics. Their effect of bacterial counts of the eyelids.

Authors:  C R Whitney; R P Anderson; M R Allansmith
Journal:  Arch Ophthalmol       Date:  1972-02

6.  Staphylococcus aureus isolated from normal and infected eyes. Phage types and sensitivity to antibacterial agents.

Authors:  D Locatcher-Khorazo; N Sullivan; E Gutierrez
Journal:  Arch Ophthalmol       Date:  1967-03

7.  Staphylococcus epidermidis (albus) endophthalmitis. Report of two cases after cataract extraction.

Authors:  M J Valenton; R F Brubaker; H F Allen
Journal:  Arch Ophthalmol       Date:  1973-02

8.  Gentamicin-resistant staphylococci.

Authors: 
Journal:  Lancet       Date:  1981-09-26       Impact factor: 79.321

Review 9.  Prophylactic antibiotics for ophthalmic surgery.

Authors:  M B Starr
Journal:  Surv Ophthalmol       Date:  1983 May-Jun       Impact factor: 6.048

10.  Management of infectious endophthalmitis.

Authors:  R K Forster; R L Abbott; H Gelender
Journal:  Ophthalmology       Date:  1980-04       Impact factor: 12.079

View more
  4 in total

1.  Effects of fusidic acid on staphylococcal keratitis.

Authors:  K F Tabbara; S Antonios; H Alvarez
Journal:  Br J Ophthalmol       Date:  1989-02       Impact factor: 4.638

2.  The antibacterial effect of topical anesthetic proparacaine on conjunctival flora.

Authors:  H Oguz; E Oguz; S Karadede; G Aslan
Journal:  Int Ophthalmol       Date:  1999       Impact factor: 2.031

3.  Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea.

Authors:  D V Seal; P Wright; L Ficker; K Hagan; M Troski; P Menday
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

4.  Lubrithal (Leo viscous eye gel), precorneal residence time in normal and dry eyes.

Authors:  S al-Mansouri; K F Tabbara; E Rask-Pedersen
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.